Company intelligence / Profile preview

EVOMEDIS

Ownership: Private
Development stage: Preclinical

Overview

EVOMEDIS has developed two main products in pre-clinical/R&D stages. EVOCellic, an allogeneic cell-based wound therapy using freeze-dried donor skin cells for immediate use in deep burns and chronic wounds; and EVOSens, a smart wound dressing that monitors pH to support optimal healing. No clinical trial results are publicly available yet.

Therapeutic areas: Dermatology
Modalities: Cell-based therapies (allogeneic cellular skin replacement)Medical devices (wound sensor bandage)
Industry: Biotech

Drug pipeline

1 asset

EVOCellic

Preclinical

Beyond the preview

Go deeper on EVOMEDIS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVOMEDIS.

Explore the full profile